Buyanghuanwu decoction (BYHWD) attenuates hepatic fibrosis in CCl4-induced mice by regulating bile acid metabolism through activating PPARα - PubMed
3 days ago
- #Liver Fibrosis
- #PPARα
- #Traditional Chinese Medicine
- Buyanghuanwu decoction (BYHWD) attenuates hepatic fibrosis in CCl4-induced mice by regulating bile acid metabolism through PPARα activation.
- BYHWD, a Traditional Chinese Medicine (TCM) formula, is traditionally used for cardiovascular and cerebrovascular diseases and shows efficacy in organ fibrosis.
- The study established a hepatic fibrosis model in mice using CCl4 and treated them with BYHWD or sorafenib.
- BYHWD reduced liver injury markers (ALT, AST), collagen deposition, and hydroxyproline content, indicating reduced fibrosis.
- It inhibited hepatic stellate cell (HSC) activation, TGF-β/Smad signaling, inflammation, and regulated arachidonic acid metabolism.
- Metabolomic and proteomic analyses revealed BYHWD's role in reversing bile acid dysregulation and upregulating PPARα expression.
- 84 liver-distributed components of BYHWD were identified, with several (e.g., Safflospermidine B, Astragaloside III) potentially targeting PPARα.
- The study concludes BYHWD's anti-fibrotic effect is mediated via PPARα activation to regulate bile acid homeostasis.
- Findings support BYHWD's clinical application for hepatic fibrosis treatment.